In the Media

First of its kind study to investigate the effects of Almond Therapy in TRD patients receiving intranasal esketamine.

The filing of two separate provisional patent applications with the United States Patent and Trademark Office (“USPTO”) related to the Company’s novel psilocybin-based drug product candidates, ZYL-312 and ZYL-314.

Announcing Mr. Jeroen Tas has joined the Company as a strategic advisor and will also act as an observer to the Board of Directors.

Announcing the establishment of the Company’s Scientific Advisory Committee and Digital Health Advisory Committee, (collectively the “Committees”), and the appointment of five highly distinguished members to the Committees.

An update on key additions to its executive leadership team that have recently taken place over the past quarter.

Announced rebranding and launch as Zylorion Health.

PsiloTec Health Solutions Inc. and Michichi Capital Corp. (TSXV: MCCP.P), a “Capital Pool Company” under TSX Venture Exchange (the “TSXV” or the “Exchange”) Policy 2.4 (the “CPC Policy”) are pleased to announce that they have entered into a non-binding letter of intent

Announcing that it has closed a non-brokered seed round Unit Offering of 10,759,000 Units at a price of $0.50 per Unit,.